目的 觀察血塞通注射液聯(lián)合比索洛爾治療冠心病心力衰竭的臨床療效。方法 選取2013年6月-2015年3月儋州市第三人民醫(yī)院收治的冠心病心力衰竭患者72例，隨機(jī)分為對照組和治療組，每組各36例。對照組口服富馬酸比索洛爾片，初始劑量為1.25 g/次，1次/d；若耐受則1周后，增加1.25 mg/次直至5 mg/次；若仍能耐受則每月增加2.5 mg/次直至10 mg/次。治療組在對照組基礎(chǔ)上靜脈滴注血塞通注射液，500 mg加入到5%葡萄糖溶液250 mL中，1次/d。兩組患者均治療2個月。觀察兩組的臨床療效，比較兩組患者心臟功能及血液流變學(xué)情況。結(jié)果 治療后，對照組和治療組的總有效率分別為77.8%、91.7%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者的紅細(xì)胞壓積、血漿黏度、全血黏度高切及全血黏度低切均顯著降低，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的降低程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者的左室射血分?jǐn)?shù)（LVEF）均顯著升高，而左室收縮末期容積（LVESV）和左室舒張末期容積（LVEDV）均顯著降低，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 血塞通注射液聯(lián)合比索洛爾治療冠心病心力衰竭具有較好的臨床療效，能增強(qiáng)心臟功能，改善血液流變學(xué)情況，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical effect of Xuesaitong Injection combined with bisoprolol in treatment of coronary heart disease complicated with heart failure. Methods Patients (72 cases) with coronary heart disease complicated with heart failure in Danzhou Third People's Hospital from June 2013 to March 2015 were randomly divided into the control and treatment groups, and each group had 36 cases. Patients in the control group were po administered with Bisoprolol Fumarate Tablets, starting dosage 1.25 mg/time, once daily, and if the patients could tolerate it, the dosage was increased for 1.25 mg/time up to 5 mg/time after 1 week, and if the patients can still tolerate it, the dosage was increased for 2.5 mg/time each month up to 10 mg/time. Patients in the treatment group were iv administered with Xuesaitong Injection on the basis of the control group, 500 mg added to 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and heart function and blood rheology in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.8% and 91.7%, respectively, and there was difference between two groups (P<0.05). After treatment, hematocrit, plasma viscosity, whole high viscosity, and low shear whole blood viscosity in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the LVEF in two groups were significantly increased, but LVESV and LVEDV in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xuesaitong Injection combined with bisoprolol has the clinical curative effect in treatment of coronary heart disease complicated with heart failure, and can enhance heart function, improve blood rheology, which has a certain clinical application value.